Salts and esters of APX3330 and therapeutic uses thereof
AssigneeOpus Genetics, Inc.
InventorsDaniela Carmen Oniciu, Corina-Mihaela Manta, Anthony Carestia, Jon Housley
Life of this patent
Estimating the term…
Loading patent…
AssigneeOpus Genetics, Inc.
InventorsDaniela Carmen Oniciu, Corina-Mihaela Manta, Anthony Carestia, Jon Housley
Estimating the term…
This invention relates to Compound 1 (APX3330) salts and esters. The invention also provides compositions comprising a Compound 1 salt or ester. The invention also provides compounds of formula (I) and formula (II) and pharmaceutically acceptable salts thereof. The invention further provides compositions comprising a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or vehicle. The invention also provides methods for treating or preventing a disease, such as cancer, a liver disorder, an ocular disorder, a cardiovascular disorder, fibrosis, or an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a Compound 1 salt or ester; or compound of formula (I) or formula (II), or pharmaceutically acceptable salt thereof.
Compound 1 calcium salt that exhibits an X-ray powder diffraction (XRPD) pattern comprising a peak at 8.0±0.2 degrees 2-theta and a peak at 10.1±0.2 degrees 2-theta, wherein said Compound 1 calcium salt is a calcium salt of (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic acid.
Compound 1 calcium salt that exhibits an XRPD pattern that is substantially the same as that depicted in FIG. 2A, wherein said Compound 1 calcium salt is a calcium salt of (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic acid.
Dependencies are inferred from the claim text.